Press Release: Complix : Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances
HASSELT, Belgium, March 31, 2021 /PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces the publication in Science Advances of the results from a joint,...
Read full article »
Complix is a biopharmaceutical firm that focuses on the discovery and development of alphabody-based therapeutics and treatment of autoimmune diseases.
Read more